Seaport Therapeutics Q2 2026 Financials and Clinical Updates

Boston, Massachusetts, USA -- Seaport Therapeutics, Inc. (Nasdaq: SPTX), a clinical-stage biotechnology company focused on neuropsychiatric medicines, released its financial results for the second quarter of 2026 and provided updates on its lead product candidates.

Clinical Progress and Pipeline Updates

• GlyphAllo (SPT-300): Enrollment is proceeding for the Phase 2b BUOY-1 trial in patients with major depressive disorder (MDD), with topline data anticipated in the first half of 2027. Additionally, a Phase 1 driving simulation trial is underway in healthy volunteers, with results expected in the second half of 2026.
• GlyphAgo (SPT-320): Following positive proof-of-concept results from a Phase 1 trial in healthy volunteers, the company plans to initiate a Phase 2a trial in patients with generalized anxiety disorder (GAD) and sleep disturbance in the second half of 2026. A Phase 2b trial for GAD is planned for the first half of 2027.
• Glyph2BLSD (SPT-348): Development of this non-hallucinogenic neuroplastogen remains on schedule, with first-in-human-enabling studies expected to complete by the end of 2027.

Financial Highlights

• Cash Position: As of June 30, 2026, the company held $427.3 million in cash, cash equivalents, and investments. This balance is expected to support operations into 2029.
• Capital Raising: In May 2026, the company successfully closed an upsized initial public offering (IPO), generating $260.0 million in gross proceeds.
• Operating Expenses: Research and development expenses for the second quarter of 2026 were $24.6 million, an increase from $13.4 million in the same quarter of 2025, driven by the advancement of clinical programs. General and administrative expenses rose to $41.2 million, largely due to non-cash stock-based compensation related to the IPO.